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Clinical trial
jective and showed a signiﬁcant reduction in the primary composite
(death from vascular causes, myocardial infarction, or stroke) with
ticagrelor compared to clopidogrel (9.8% vs. 11.7%, Hazard Ratio [HR]
0.84, 95% conﬁdence interval [CI]: 0.77–0.92, p b 0.001, respectively).
There were also signiﬁcant reductions of the individual endpoints of
total death, cardiovascular death, myocardial infarction and stent
thrombosis. There were no differences in overall major bleeding but a
signiﬁcant increase in non-procedure related major bleeding. The re-
sults were consistent across 32 different predeﬁned subgroups except
for geographywhere there was an interaction and an indication of a dif-
ferent efﬁcacy result in North America [2].Four years ago we presented the ﬁrst results from Platelet Inhibition
and Patient Outcomes (PLATO) trial testing the superiority of ticagrelor
as compared with clopidogrel in 18,624 patients with ST-elevationh Center, Uppsala University,
).
land Ltd. Open access under CC BY-NCmyocardial infarction (STE-MI) or non-ST-elevation acute coronary syn-
dromes (NSTE-ACS) from 41 countries [1]. The trial met its primary ob-
The PLATO study group has since 2009 performed, presented and, in
major medical scientiﬁc journals, published a long series of predeﬁned
and post-hoc analyses to further explore and better understand the ef-
fects of ticagrelor. The results have been very consistent with similar re-
sults in patients with STEMI or NSTE-ACS [3], intention for invasive or
non-invasive treatment [4,5], diabetesmellitus or not [6], renal dysfunc-
tion or not [7], elderly or younger [8], non-smokers or smokers [9], pul-
monary disease or not [10,11] and previous stroke or not [12]. Stent
thrombosis was reduced both with bare-metal and drug eluting stents
when compared with both higher and lower clopidogrel loading doses
[13]. The reduction of mortality was shown caused by a combination
of less cardiovascular, bleeding and infection-related deaths [14].
The reduction of cardiovascular events was consistent both in patients
with and without CYP2C19 loss-of-function polymorphisms [15].-ND license. 
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in the U.S. was found likely explained by an interactionwith the use of a
high dose aspirin in about half of the patients in North-America, which
was in accordance with a similar lack of efﬁcacy in the very small pro-
portion with a high aspirin dose in the rest of the world, although
chance alone cannot be excluded as an explanation [16]. No interaction
has been shown with other medications e.g. proton-pump inhibitors
[17]. The reduction in event rate by ticagrelor has also been shown con-
sistent over time with a reduction not only of the ﬁrst but also of the
total number of events over the whole treatment period [18]. Finally
the cost-effectiveness analysis shows a very favorable incremental
cost per life-year gained [19].
These results have led to regulatory approval of ticagrelor for the
treatment of STEMI and NSTE-ACS in 100 countries worldwide. Further-
more the European, AHA/ACC and other guideline committees now
are recommending ticagrelor as a ﬁrst line treatment both in STEMI
treated with primary PCI and in NSTE-ACS regardless if an invasive or
non-invasive treatment strategy is used [20–22]. Importantly the up-
take of ticagrelor as the preferred P2Y12 inhibitor has been rapid in
many countries, not least in Europe, where now further improved sur-
vival and reduction of recurrent ischaemic events can be expected. Be-
cause of the geographical heterogeneity with a lack of beneﬁt of
ticagrelor in the U.S. cohort the FDA reviewers very critically andmetic-
ulously scrutinized the ticagrelor submission. Therefore there passed
around a year before the publication of all FDA internal documents in
2011. After a public and internal discussion of all available information
FDA approval was granted based on the 8 out of 9 favorable votes at
the advisory committee meeting.
Two individuals have in a number of publications, several of which
in IJC, repeated their doubts about the validity of the PLATO results. In
a recent paper in International Journal of Cardiology in August 2013,
one of these authors is allowed to publish serious accusations that the
PLATO trial academic leadership, operational staff, investigators, moni-
tors, event adjudicators and the sponsor have committed illegal and
fraudulent actions by secretly breaking the blinding of the study treat-
ment and intentionally deleted, concealed, underreported, downgraded
or misadjudicated events in patients that they are claimed to have
known were assigned to ticagrelor (by unknown means) [23].
In the paper [23] the authors present analyses, without describing
the statistical methodology, based on reported outcomes in 10 out of
41 countries claiming that monitoring of the study by the sponsor
should have providedmore favorable results of ticagrelor thanmonitor-
ing by a CRO. This issue has however already previously been addressed
by two senior academic statisticians using advanced multivariable sta-
tistical technologies based on the whole study population in all the 41
countries [24]. The complete results were recently published in a
peer-reviewed journal concluding that: “When examined in the overall
population of patients, there was a treatment by monitoring source in-
teraction andmonitoring source appears to account for 61% of the treat-
ment by region interaction. While this is an interesting observation, all
U.S. sites were monitored by non-Sponsor personnel. Hence, it is likely
that treatment by region and treatment by monitor interactions are
strongly confounded and lead to an expectation that both are individu-
ally explained by the interaction of treatment and ASA maintenance
dose. A sequence of Cox regression models was applied to the data in
an attempt to better appreciate the interplay between region, monitor-
ing source and ASA maintenance dose. These analyses conﬁrmed the
stated expectation. Hence, while it is not possible to draw ﬁrm conclu-
sions about whether monitoring source is an independent contributor
or explanatory effect, it appears that ASA maintenance dose remains
the dominant covariate in explaining the interaction between region
and randomized treatment.” Thus, based on appropriate statistical anal-
yses there is no reason to suspect an inﬂuence of monitoring organiza-
tion on the study outcomes in the PLATO trial.
In the IJC manuscript there are completely unfounded accusations
that the PLATO study was not adequately blinded [23]. In contrast, thePLATO trial was a carefully blinded study in accordance with the GCP
guidelines. According to the protocol, the treatment code should not
be broken except in medical emergencies when the appropriate man-
agement of the patient necessitates knowledge of the treatment ran-
domization. In order to meet FDA and other regulatory agencies
reporting requirements, for expedited SAE reporting, Suspected Unex-
pected Serious Adverse Reactions (SUSAR), Patient Safety personnel
not directly involved with the conduct of the study were unblinded in
order to appropriately process SAE reports. This is a common procedure
in clinical outcome studies, in order to secure patient safety during
study conduct. In the full analysis set 452 out of 18,624 patients were
unblinded for any reason prior to database lock (DBL). Therewas no im-
balance between treatment arms. 238 (2.6%) patients randomized to
ticagrelor were unblinded by any reason prior to DBL, as compared to
214 (2.3%) of the patients randomized to clopidogrel. In many of these
cases unblinding did occur after patients had completed the random-
ized study period event free or after experiencing an event comprised
by the primary endpoint. 155 (1.7%) of the patients randomized to
ticagrelor were unblinded while still contributing to the primary analy-
sis, as compared to 118 (1.3%) of those randomized to clopidogrel. The
number of patients being unblinded prior to experiencing an event in-
cluded in the primary endpoint was also similar between treatment
arm, 13 on ticagrelor and 15 on clopidogrel. To demonstrate that
unblinding of treatment allocation prior to a primary endpoint did not
affect the outcome of the study, all 15 patients randomized to
clopidogrel, with a treatment allocation known to anyone prior to the
occurrence of the event, were censored at the earliest occasion of
unblinding. The results of this sensitivity analysis veriﬁed that the dif-
ference in the primary composite endpoint remained statistically signif-
icant. These results were submitted to the FDA in response to questions
from the FDA reviewer prior to approval of ticagrelor. The FDA reviewer
found one misclassiﬁed patient, among 389 who were unblinded for
SUSAR reporting, but refers to no other errors despite having access to
full data set for the entire 18,624 patients (corresponding to 0.005%).
The FDADivision Director has the following comment on this issue: “Al-
though Dr. Marciniak seems suspicious, neither he nor DSI found evi-
dence of sponsor misbehaviour. Considering the effort Dr. Marciniak
expended on review of individual cases, he found relatively few prob-
lems of any kind. As far as I can tell, data quality issues are not of great
concern.”
The IJC paper also accuses the PLATO trial for unfair reporting and
analyses of myocardial infarction and present some tables on this
issue based on data accumulated from a diversity of documents
[23]. These results are not in agreement with our recently presented
analyses of myocardial infarction using the raw data sets from all indi-
vidual PLATO patients (Mahaffey K et al, ACC Scientiﬁc Sessions,
March 2013). The following is a summary of these results. “In the
PLATO trial a central clinical events committee (CEC) prospectively de-
ﬁned and adjudicated all suspected MI events. Treatment comparisons
used CEC-adjudicated data and, per protocol, excluded silent MI. Over-
all, 1300 (611 ticagrelor, 689 clopidogrel) MIs reported by the CEC oc-
curred during the trial. Of these, 1097 (504 ticagrelor, 593 clopidogrel)
contributed to the primary composite endpoint. Site investigators re-
ported 1198 (580 ticagrelor, 618 clopidogrel) MIs. Ticagrelor reduced
overall 12-month Kaplan–Meier MI rates (5.8% ticagrelor, 6.9%
clopidogrel; hazard ratio [HR]: 0.84; 95% conﬁdence interval [CI]:
0.75–0.95). Analyses of overall MI using site investigator reported data
showed similar results HR: 0.88; 95% CI: 0.78–1.00.” Thus, in contrast
to what is stated in the IJC manuscript, ticagrelor signiﬁcantly reduced
the incidence of MI compared with clopidogrel, with consistent results
both based on CEC evaluation and site reporting.
Most other issues raised in the IJC manuscript [23] are copied from
the FDA Documents andmainly from the statements of theMedical Re-
viewer Dr. Marciniak. These questions have already previously been ad-
dressed by the FDADivisionDirector Dr. Norman Stockbridge in his ﬁnal
report on the PLATO trial evaluation, which also is available in the FDA
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quality issues overall were few and of no great concern in relation to the
anecdotal cases that the Medical Reviewer considered problematic. The
FDA Division comments on the data quality in his review prior to the ap-
proval of ticagrelor: “Dr. Marciniak's review contains anecdotes for (23)
cases he considers problematic. These amounts to about one case per
1000 subjects enrolled, butwithout subject IDs some of the descriptions
may refer to the same subject. Importantly, Dr. Marciniak's review gives
little insight into how cases came under his scrutiny, so the possibility
exists for the inadvertent introduction of bias in case selection. Thus,
one has to decide whether the total number of problems identiﬁed by
Dr. Marciniak is enough to call for re-evaluation or a new study, but I
do not believe that one can make reliable inference from the distribu-
tion of cases Dr. Marciniak identiﬁed by treatment groups.”
As experienced scientists, authors of many scientiﬁc papers and
members of editorial boards of several journals we are amazed that IJC
publishes these unfounded accusations of fraudulent behavior in the
PLATO trial. We ﬁnd such allegations unacceptable in a peer-reviewed
scientiﬁc journal especially when based on erroneous data, improper
statistical methodology, and severely biased citations of already refuted
data and statements from other publications and a long series of self-
citations. Given the severity of the accusations made, we would have
expected the IJC editors to provide the PLATO authors an opportunity
to review and respond to this manuscript before committing to its pub-
lication. As members of the cardiovascular scientiﬁc community, we
support the notions of open access to analyses of data as one more
way to assure validity of clinical trial information. The complete
PLATO database is available at two independent academic institutions,
which continuously perform and publish new analyses in peer-
reviewed major scientiﬁc journals based on requests from and collabo-
ration between the PLATO investigators and involving also other inves-
tigators. Unfortunately the paper in IJC is an example of the dangers of
open access to data when the peer review and editorial processes fail
to do due diligence.
The results of the PLATO as other clinical trials with ticagrelor have
fully been disclosed in documents from regulatory agencies and exten-
sively published in peer-reviewed journals and are of course open for
scientiﬁc discussion and debate. Any reader of scientiﬁc papers should
be able to review the results critically, draw conclusions and translate
the results into clinical practice. In doing so, the reader can be conﬁdent
that the reported DSMB monitored, regulatory agency scrutinized and
peer-reviewed published data from the PLATO trial, as well as from
other meticulously performed clinical trials, are correct and reported
without bias. This extremely well regulated process might seem both
overly slow and forbiddingly costly but is still the safest way to bring
new innovative treatments to our patients. Based on such a long process
with PLATO, now is the time to switch from investigation to implemen-
tation of ticagrelor in the majority of patients with acute coronary
syndrome in order to improve their survival and reduce the risk of re-
current events.
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